Sinovac Biotech Ltd (SVA) FinancialsSVASinovac Biotech Ltd

Evaluating the bottom line, Sinovac Biotech Ltd maintains a gross margin of 62.53%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -144.56%, while the net margin is -74.12%. These profitability ratios, combined with a Return on Equity (ROE) of -0.38%, provide a clear picture of how effectively SVA converts its operational activities into shareholder value.

In the context of the broader market, SVA competes directly with industry leaders such as RLMD and PBYI. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, SVA's gross margin of 62.53% stands against RLMD's N/A and PBYI's 77.88%. Such benchmarking helps identify whether Sinovac Biotech Ltd is trading at a premium or discount relative to its financial performance.

The financial performance shows concerning metrics, including a negative P/E ratio of -1.87 and a forward P/E of 357.14, indicating potential overvaluation and lack of profitability.